Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1387488

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1387488

Cancer Monoclonal Antibodies Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Cancer Monoclonal Antibodies Trends and Forecast

The future of the global cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets. The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030 with a CAGR of 12.4% from 2024 to 2030. The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

A more than 150-page report is developed to help in your business decisions.

Cancer Monoclonal Antibodies by Segment

The study includes a forecast for the global cancer monoclonal antibodies by type, application, end use, and region.

Cancer Monoclonal Antibodies Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Humanized
  • Human
  • Chimeric
  • Murine

Cancer Monoclonal Antibodies Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Liver Cancer
  • Others

Cancer Monoclonal Antibodies Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Research Institutes
  • Others

Cancer Monoclonal Antibodies Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Monoclonal Antibodies Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer monoclonal antibodies companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer monoclonal antibodies companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie

Cancer Monoclonal Antibodies Market Insights

Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Within this market, hospitals will remain the largest segment due increasing prevalence of cancer along with growing number of patient hospitalizations.

North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Features of the Global Cancer Monoclonal Antibodies Market

Market Size Estimates: Cancer monoclonal antibodies market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer monoclonal antibodies market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Cancer monoclonal antibodies market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the cancer monoclonal antibodies market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer monoclonal antibodies market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cancer monoclonal antibodies market size?

Answer: The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030.

Q2. What is the growth forecast for cancer monoclonal antibodies market?

Answer: The global cancer monoclonal antibodies market is expected to grow with a CAGR of 12.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cancer monoclonal antibodies market?

Answer: The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

Q4. What are the major segments for cancer monoclonal antibodies market?

Answer: The future of the cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets.

Q5. Who are the key cancer monoclonal antibodies market companies?

Answer: Some of the key cancer monoclonal antibodies companies are as follows:

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie

Q6. Which cancer monoclonal antibodies market segment will be the largest in future?

Answer: Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Q7. In cancer monoclonal antibodies market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer monoclonal antibodies market by type (humanized, human, chimeric, and murine), application (blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, and others), end use (hospitals, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Monoclonal Antibodies Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Monoclonal Antibodies Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Monoclonal Antibodies Market by Type
    • 3.3.1: Humanized
    • 3.3.2: Human
    • 3.3.3: Chimeric
    • 3.3.4: Murine
  • 3.4: Global Cancer Monoclonal Antibodies Market by Application
    • 3.4.1: Blood Cancer
    • 3.4.2: Breast Cancer
    • 3.4.3: Lung Cancer
    • 3.4.4: Melanoma
    • 3.4.5: Colorectal Cancer
    • 3.4.6: Liver Cancer
    • 3.4.7: Others
  • 3.5: Global Cancer Monoclonal Antibodies Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Research Institutes
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Monoclonal Antibodies Market by Region
  • 4.2: North American Cancer Monoclonal Antibodies Market
    • 4.2.2: North American Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.3: European Cancer Monoclonal Antibodies Market
    • 4.3.1: European Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.3.2: European Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.4: APAC Cancer Monoclonal Antibodies Market
    • 4.4.1: APAC Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.4.2: APAC Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.5: ROW Cancer Monoclonal Antibodies Market
    • 4.5.1: ROW Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.5.2: ROW Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Type
    • 6.1.2: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Application
    • 6.1.3: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Region
  • 6.2: Emerging Trends in the Global Cancer Monoclonal Antibodies Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Monoclonal Antibodies Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Monoclonal Antibodies Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Bristol Myers Squibb
  • 7.3: Merck
  • 7.4: GlaxoSmithKline
  • 7.5: Johnson & Johnson
  • 7.6: Amgen
  • 7.7: Novartis
  • 7.8: AstraZeneca
  • 7.9: Eli Lilly
  • 7.10: AbbVie
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!